4881 Stock Overview
FunPep Company Limited engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices based on functional peptides.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
FunPep Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥143.00 |
| 52 Week High | JP¥325.00 |
| 52 Week Low | JP¥118.00 |
| Beta | 0.68 |
| 1 Month Change | -18.29% |
| 3 Month Change | 3.62% |
| 1 Year Change | -23.53% |
| 3 Year Change | -67.79% |
| 5 Year Change | n/a |
| Change since IPO | -81.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4881 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | -2.7% | -2.8% | -2.6% |
| 1Y | -23.5% | -28.6% | 28.4% |
Return vs Industry: 4881 exceeded the JP Biotechs industry which returned -28.6% over the past year.
Return vs Market: 4881 underperformed the JP Market which returned 28.4% over the past year.
Price Volatility
| 4881 volatility | |
|---|---|
| 4881 Average Weekly Movement | 17.4% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in JP Market | 8.2% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 4881's share price has been volatile over the past 3 months.
Volatility Over Time: 4881's weekly volatility has increased from 10% to 17% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 15 | Toshimi Miyoshi | www.funpep.co.jp |
FunPep Company Limited engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices based on functional peptides. The company is developing SR-0379, a functional peptide for skin ulcer; FPP003, an antibody-inducing peptide that is in Phase II clinical study for the treatment of psoriasis in Australia, as well as phase II clinical trial for ankylosing spondylitis in Japan; and FPP004X, an antibody-inducing peptide for pollinosis. It is also developing FPP006, a corona peptide vaccine; and FPP005, a antibody including peptide for psoriasis.
FunPep Company Limited Fundamentals Summary
| 4881 fundamental statistics | |
|---|---|
| Market cap | JP¥3.90b |
| Earnings (TTM) | -JP¥933.00m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.0x
P/E RatioIs 4881 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4881 income statement (TTM) | |
|---|---|
| Revenue | JP¥0 |
| Cost of Revenue | JP¥0 |
| Gross Profit | JP¥0 |
| Other Expenses | JP¥933.00m |
| Earnings | -JP¥933.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 13, 2024
| Earnings per share (EPS) | -36.10 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 4881 perform over the long term?
See historical performance and comparison